Provider: NIHR Journals Library
Content:text/plain; charset="UTF-8"
TY  - GEN
LB  - 1.
AU  - National Collaborating Centre for Cancer
TI  - CG58 NICE full guideline, Prostate cancer: diagnosis and treatment
CY  - Cardiff
PY  - 2008
ER  - 
TY  - BOOK
LB  - 2.
AU  - Sutcliffe, P
AU  - Hummel,, S
AU  - Simpson, E
AU  - Young, T
AU  - Rees, A
AU  - Wilkinson, A
TI  - Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review
PB  - Technology Assessment Report commissioned by the NHS R&D HTA programme
PY  - 2007
SP  - 1
EP  - 2218
ER  - 
TY  - JOUR
LB  - 3.
AU  - Hsing, AW
AU  - Chokkalingham, AP
TI  - Prostate cancer epidemiology
J2  - Frontiers in Bioscience
PY  - 2006
VL  - 11
SP  - 1388
EP  - 1413
ER  - 
TY  - BOOK
LB  - 4.
AU  - Burford, DC
AU  - Kirby, M
AU  - Austoker, J
TI  - Prostate cancer risk management programme: information for primary care. PSA testing in asymptomatic men
ET  - 2nd
PB  - NHS Cancer Screening Programmes
PY  - 2009
ER  - 
TY  - JOUR
LB  - 5.
AU  - Hamilton, W
AU  - Sharp, D
TI  - Symptomatic diagnosis of prostate cancer in primary care: a structured review
J2  - Br J Gen Pract
PY  - 2004
VL  - 54
SP  - 617
EP  - 621
ER  - 
TY  - JOUR
LB  - 6.
AU  - Garnick, MB
TI  - Prostate cancer: screening, diagnosis and management
J2  - Ann Intern Med
PY  - 1993
VL  - 118
SP  - 804
EP  - 818
ER  - 
TY  - JOUR
LB  - 7.
AU  - Royal College of General Practitioners, Prostate cancer: Diagnosis and treatment
J2  - EGP Update
PY  - 2009
ER  - 
TY  - JOUR
LB  - 8.
AU  - Collin, SM
AU  - Metcalfe, C
AU  - Donovan, J
AU  - Lane, JA
AU  - Davis, M
AU  - Neal, D
TI  - Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study
J2  - BJU Int
PY  - 2008
VL  - 102
SP  - 1400
EP  - 1406
ER  - 
TY  - JOUR
LB  - 9.
AU  - Johansson, JE
AU  - Andren, O
AU  - Andersson, SO
AU  - Dickman, PW
AU  - Holmberg, L
AU  - Magnuson, A
TI  - Natural history of early localised prostate cancer
J2  - JAMA
PY  - 2004
VL  - 291
SP  - 2713
EP  - 2719
ER  - 
TY  - JOUR
LB  - 10.
AU  - Widmark, A
AU  - Klepp, O
AU  - Solberg, A
AU  - Damber, JE
AU  - Angelsen, A
AU  - Fransoon, P
TI  - Scandinavian Prostate Cancer Group Study 7, Swedish Association for Urological Oncology 3, and Endocrine treatment, with or without radiotherapy, in locally advaned prostate cancer (SPcg-7/SFUO-3): an open randomised phase III trial
J2  - Lancet
PY  - 2009
VL  - 373
SP  - 301
EP  - 308
ER  - 
TY  - JOUR
LB  - 11.
AU  - UK Clinical Research Network: Portfolio Database and ProSTART
TI  - A Phase III study of active surveillance therapy against radical treatment in patioents diagnosed with favourable risk prostate cancer (START)
J2  - UKCRN
PY  - 2009
ER  - 
TY  - JOUR
LB  - 12.
AU  - Mason, M
AU  - Warde, P
AU  - Sydes, M
AU  - Cowan, R
AU  - James, N
AU  - Kirkbride, P
TI  - The National Cancer Institute of Canada Clinical Trials Group PR3/Medical Research Council PR07 Trial Management Group. Defining the need for local therapy in locally advanced prostate cancer: an appraisal of the MRC PR07 Study
J2  - Clin Oncol
PY  - 2005
VL  - 17
SP  - 217
EP  - 218
ER  - 
TY  - JOUR
LB  - 13.
AU  - Melia, J
TI  - Part 1: The burden of prostate cancer, its natural history, information on the outcome of screening and estimates of ad hoc screening with particular reference to England and Wales
J2  - BJU Int
PY  - 2005
VL  - 95
IS  - Suppl. 3
SP  - 4
EP  - 15
ER  - 
TY  - ELEC
LB  - 14.
AU  - Cancer Research UK
TI  - 2008
TI  - Prostate Cancer – UK incidence statistics
UR  - http://info.cancerresearchuk.org/cancerstats/types/prostate/incidence/
M1  - June 2009
ER  - 
TY  - JOUR
LB  - 15.
AU  - Sakr, W
AU  - Grignon, DJ
AU  - Haas, GP
AU  - Heilbrun, LK
AU  - Pontes, JE
AU  - Crissman, JD
TI  - Age and racial distribution of prostatic intraepithilial neoplasia
J2  - Eur Urol
PY  - 1996
VL  - 30
SP  - 138
EP  - 144
ER  - 
TY  - GEN
LB  - 16.
AU  - Office for National Statistics
TI  - Cancer statistics: registrations, Registrations of cancer diagnosed in 2005, England
PB  - Office for National Statistics
PY  - 2008
ER  - 
TY  - JOUR
LB  - 17.
AU  - Chamberlain, J
AU  - Melia, J
AU  - Moss, S
AU  - Brown, J
TI  - The diagnosis, management, treatment and costs of prostate cancer in England and Wales
J2  - Health Technol Assess
PY  - 1997
VL  - 1
IS  - 3
ER  - 
TY  - JOUR
LB  - 18.
AU  - Borre, M
AU  - Nerstrom, B
AU  - Overgaard, J
TI  - The dilemma of prostate cancer: a growing human and economic burden irrespective of treatment strategies
J2  - Acta Oncol
PY  - 1997
VL  - 36
SP  - 681
EP  - 687
ER  - 
TY  - JOUR
LB  - 19.
AU  - Cozzarini, C
AU  - Fiorino, C
AU  - Di Muzio, N
AU  - Valdagni, R
AU  - Salonia, A
AU  - Alongi, F
TI  - Hypofractionated adjuvant radiotherapy with helical Tomotherapy after radical prostatectomy: Planning data and toxicity results of a Phase I-II study
J2  - Radiother Oncol
PY  - 2008
VL  - 88
SP  - 26
EP  - 33
ER  - 
TY  - JOUR
LB  - 20.
AU  - Wiegel, T
AU  - Bottke, D
AU  - Steiner, U
AU  - Siegmann, A
AU  - Golz, R
AU  - Storkel, S
TI  - Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96–02/AUO AP 09/95
J2  - J Clin Oncol
PY  - 2009
VL  - 27
SP  - 2924
EP  - 2930
ER  - 
TY  - JOUR
LB  - 21.
AU  - Thompson, LM
AU  - Tangen, CM
AU  - Paradelo, J
AU  - Lucia, MS
AU  - Miller, G
AU  - Troyer, D
TI  - Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow up of a randomized clinical trial
J2  - J Urol.
PY  - 2009
VL  - 181
SP  - 956
EP  - 962
ER  - 
TY  - JOUR
LB  - 22.
AU  - Berney, DM
AU  - Fisher, G
AU  - Kattan, MW
AU  - Oliver, TD
AU  - Moller, H
AU  - Fearn, P
TI  - Transatlantic Porstate Group. Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading
J2  - BJU Int
PY  - 2007
VL  - 100
SP  - 1240
EP  - 1244
ER  - 
TY  - JOUR
LB  - 23.
AU  - Veldeman, L
AU  - Madani, I
AU  - Hulstaert,, F
AU  - De Meerleer, G
AU  - Mareel, M
AU  - De Neve, W
TI  - Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies
J2  - Lancet Oncol
PY  - 2008
VL  - 9
SP  - 367
EP  - 375
ER  - 
TY  - JOUR
LB  - 24.
AU  - Brierley, J
TI  - The evolving TNM cancer staging system: an essential component of cancer care
J2  - CMAJ
PY  - 2006
VL  - 172
SP  - 155
EP  - 156
ER  - 
TY  - GEN
LB  - 25.
AU  - American Joint Committee on Cancer
TI  - AJCC Cancer Staging Manual
ET  - 7th
CY  - New York, NY
PB  - Springer-Verlag
PY  - 2009
ER  - 
TY  - JOUR
LB  - 26.
AU  - Schroder, FH
AU  - Hermanek, P
AU  - Denis, L
AU  - Fair, WR
AU  - Gospodarowicz, MK
AU  - Pavone-Macaluso, M
TI  - The TNM classification of prostate cancer
J2  - Prostate Suppl
PY  - 1992
VL  - 4
SP  - 129
EP  - 138
ER  - 
TY  - JOUR
LB  - 27.
AU  - Hummel, S
AU  - Paisley, S
AU  - Morgan, A
AU  - Currie, E
AU  - Brewer, N
TI  - Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review
J2  - Health Technol Assess
PY  - 2003
VL  - 7
IS  - 33
ER  - 
TY  - JOUR
LB  - 28.
AU  - Kupelian, PA
AU  - Reddy, CA
AU  - Klein, EA
AU  - Willoughby, TR
TI  - Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: Preliminary results on late toxicity and quality of life
J2  - Int J Radiat Oncol Biol Phys
PY  - 2001
VL  - 51
SP  - 988
EP  - 993
ER  - 
TY  - JOUR
LB  - 29.
AU  - Shu, HK
AU  - Lee, TT
AU  - Vigneauly, E
AU  - Xia, P
AU  - Pickett, B
AU  - Phillips, TL
TI  - Toxicity following high-dose three-dimensional conformal and intensity-modulated radiation therapy for clinically localized prostate cancer
J2  - Urology
PY  - 2001
VL  - 57
SP  - 102
EP  - 107
ER  - 
TY  - JOUR
LB  - 30.
AU  - Selley, S
AU  - Donovan, J
AU  - Faulkner, A
AU  - Coast, J
AU  - Gillatt, D
TI  - Diagnosis, management and screening of early localised prostate cancer
J2  - Health Technol Assess
PY  - 1997
VL  - 1
IS  - 2
ER  - 
TY  - JOUR
LB  - 31.
AU  - Jewett, HJ
TI  - The present status of radical prostetectomy for stages A and B prostatic cancer
J2  - Urol Clin North Am
PY  - 1975
VL  - 2
SP  - 105
EP  - 124
ER  - 
TY  - JOUR
LB  - 32.
AU  - Fitzpatrick, JM
AU  - Shulman, C
AU  - Zlotta, AR
AU  - Schroder, FH
TI  - Prostate cancer: a serious disease suitable for prevention
J2  - BJU Int
PY  - 2009
VL  - 103
SP  - 864
EP  - 870
ER  - 
TY  - JOUR
LB  - 33.
AU  - Lamb, DS
AU  - Slaney, D
AU  - Nacey, JN
AU  - Russell, G
AU  - Scott, B
AU  - Johnson, CA
TI  - Prostate cancer: the new evidence base for diagnosis and treatment
J2  - Pathol
PY  - 2007
VL  - 39
SP  - 537
EP  - 544
ER  - 
TY  - JOUR
LB  - 34.
AU  - Rosario, DJ
AU  - Lane, JA
AU  - Metcalfe, C
AU  - Catto, JWF
AU  - Dedman, D
AU  - Donovan, JL
TI  - Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study
J2  - Eur Urol
PY  - 2008
VL  - 53
SP  - 777
EP  - 784
ER  - 
TY  - ELEC
LB  - 35.
AU  - National Comprehensive Cancer Network
TI  - NCCN Clinical Practice Guidelines in Oncology: Prostate cancer 2009
UR  - www.nccn.org/professionals/physician_gls/f_guidelines.asp
M1  - May 2009
ER  - 
TY  - ELEC
LB  - 36.
AU  - Radiation Therapy Oncology Group
TI  - A short history of RTOG
PY  - 2009
UR  - www.rtog.org
M1  - May 2009
ER  - 
TY  - GEN
LB  - 37.
AU  - National Cancer Institute CTCAE v4.0 MedDRA v12.0
TI  - National Cancer Institute, Cancer Therapy Evaluation Program
PY  - 2009
ER  - 
TY  - GEN
LB  - 38.
AU  - Kumar, S
AU  - Shelley, M
AU  - Harrison, C
AU  - Coles, B
AU  - Wilt, TJ
AU  - Mason, MD
TI  - Neoadjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer
TI  - Cochrane Database Syst Rev
PY  - 2006
UR  - 10.1012/14651858.CD006019.pub2
ER  - 
TY  - JOUR
LB  - 39.
AU  - Shelley, MD
AU  - Kumar, S
AU  - Coles, B
AU  - Wilt, T
AU  - Staffurth, J
AU  - Mason, MD
TI  - Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: A systematic review and meta-analysis of randomised trials
J2  - Cancer Treat Rev
PY  - 2009
VL  - 35
SP  - 540
EP  - 546
ER  - 
TY  - JOUR
LB  - 40.
AU  - Shelley, MD
AU  - Kumar, S
AU  - Wilt, T
AU  - Staffurth, J
AU  - Coles, B
AU  - Mason, MD
TI  - A systematic review and meta-analysis of randomised trials of neoadjuvant hormone therapy for localised and locally advanced prostate carcinoma
J2  - Cancer Treat Rev
PY  - 2009
VL  - 35
SP  - 9
EP  - 17
ER  - 
TY  - JOUR
LB  - 41.
AU  - Yoshimura, K
AU  - Kamoto, T
AU  - Nakamura, E
AU  - Segawa, T
AU  - Kamba, T
AU  - Takahashi, T
TI  - Health-related quality-of-life after external beam radiation therapy for localized prostate cancer: intensity-modulated radiation therapy versus conformal radiation therapy
J2  - Prostate Cancer Prostatic Dis
PY  - 2006
VL  - 10
SP  - 288
EP  - 292
ER  - 
TY  - JOUR
LB  - 42.
AU  - Bellizzi, KM
AU  - Latini, DM
AU  - Cowan, JE
AU  - DuChane, J
AU  - Carroll, PR
TI  - Fear of recurrence, symptom burden, and health-related quality of life in men with prostate cancer
J2  - Urology
PY  - 2008
VL  - 72
SP  - 1269
EP  - 1273
ER  - 
TY  - JOUR
LB  - 43.
AU  - Lips, I
AU  - Dehnad, H
AU  - Kruger, AB
AU  - van Moorselaar, J
AU  - van der Heide, U
AU  - Battermann, J
TI  - Health-related quality of life in patients with locally advanced prostate cancer after 76 GY intensity-modulated radiotherapy vs. 70 GY conformal radiotherapy in a prospective and longitudinal study
J2  - Int J Radiat Oncol Biol Phys
PY  - 2007
VL  - 69
SP  - 656
EP  - 661
ER  - 
TY  - JOUR
LB  - 44.
AU  - American Society for Therapeutic Radiology and Oncology Consensus Panel
TI  - Consensus statement: guidelines for PSA following radiation therapy
J2  - Int J Radiat Oncol Biol Phys
PY  - 1997
VL  - 37
SP  - 1035
EP  - 1041
ER  - 
TY  - JOUR
LB  - 45.
AU  - Roach, M, III
AU  - Hanks, G
AU  - Thames, H, Jr
AU  - Schellhammer, P
AU  - Shipley, WU
AU  - Sokol, GH
TI  - Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference
J2  - Int J Radiat Oncol Biol Phys
PY  - 2006
VL  - 65
SP  - 965
EP  - 974
ER  - 
TY  - JOUR
LB  - 46.
AU  - Kupelian, PA
AU  - Buchsbaum, JC
AU  - Patel, C
AU  - Elshaikh, M
AU  - Reddy, CA
AU  - Zippe, CD
TI  - Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era
J2  - Int J Radiat Oncol Biol Phys
PY  - 2002
VL  - 52
SP  - 704
EP  - 711
ER  - 
TY  - BOOK
LB  - 47.
AU  - Van den Steen, D
AU  - Hulstaert, F
AU  - Camberlin, C
TI  - Intensity-modulated radiotherapy (IMRT)
CY  - Health Technology Assessment (HTA). Brussels
PB  - Belgian Health Care Knowledge Centre (KCE)
PY  - 2007
ER  - 
TY  - JOUR
LB  - 48.
AU  - Lips, IR
AU  - Dehnad, H
AU  - Van Gils, CH
AU  - Boeken Kruger, AE
AU  - van der Heide, UA
AU  - Van Vuplen, M
TI  - High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial; marker-based position verification: acute and late toxicity in 331 patients
J2  - Radiat Oncol
PY  - 2008
VL  - 3
SP  - 15
ER  - 
TY  - JOUR
LB  - 49.
AU  - Chen, MJ
AU  - Weltman, E
AU  - Hanriot, RM
AU  - Luz, FP
AU  - Cecilio, PJ
AU  - da Cruz, JC
TI  - Intensity modulated radiotherapy for localized prostate cancer: rigid compliance to dose-volume constraints as a warranty of acceptable toxicity?
J2  - Radiat Oncol
PY  - 2007
VL  - 2
SP  - 6
ER  - 
TY  - GEN
LB  - 50.
AU  - National Institute for Health and Clinical Excellence
TI  - Prostate cancer: diagnosis and treatment
PY  - 2008
ER  - 
TY  - GEN
LB  - 51.
AU  - Department of Health
TI  - NHS reference costs 2007–8
PY  - 2009
ER  - 
TY  - BOOK
LB  - 52.
AU  - Cross, T
AU  - McPhail, S
TI  - Prostate cancer: diagnosis and treatment: an assessment of need
CY  - London
PB  - National Institute for Health and Clinical Excellence
PY  - 2008
ER  - 
TY  - GEN
LB  - 53.
AU  - The Royal College of Radiologists
TI  - Development and Implementation of Conformal radiotherapy in the United Kingdom
CY  - London
PB  - Royal College of Radiologists
PY  - 2002
ER  - 
TY  - GEN
LB  - 54.
AU  - Advice to the Naitonal Radiotherapy Advisory Group (NRAG)
TI  - National Radiotherapy Advisory Group Radiotherapy Technical Development sub-group
PB  - NRAG
PY  - 2007
ER  - 
TY  - RPRT
LB  - 55.
AU  - International Commission on Radiation Units and Measurements
TI  - ICRU report 50: Prescribing, Recording and Reporting Photon Beam Therapy
CY  - Bethesda, MD
PB  - International Commission on Radiation Units and Measurements
PY  - 1993
ER  - 
TY  - RPRT
LB  - 56.
AU  - International Commission on Radiation Units and Measurements
TI  - ICRU report 62: Prescribing, Recording and Reporting Photon Beam Therapy
CY  - Bethesda, MD
PB  - International Commission on Radiation Units and Measurements
PY  - 1999
ER  - 
TY  - JOUR
LB  - 57.
AU  - Brahme, A
TI  - Optimization of stationary and moving beam raiation therapy techniques
J2  - Radiother Oncol
PY  - 1988
VL  - 12
SP  - 129
EP  - 140
ER  - 
TY  - JOUR
LB  - 58.
AU  - Webb, S
TI  - Optimisation of conformal radiotherapy dose distributions by simulated annealing
J2  - Phys Med Biol
PY  - 1989
VL  - 34
SP  - 1349
EP  - 1370
ER  - 
TY  - JOUR
LB  - 59.
AU  - Peeters, ST
AU  - Heemsbergen, WD
AU  - Koper, PC
AU  - van Putten, WL
AU  - Slot, A
AU  - Dielwart, MF
TI  - Dose–response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy
J2  - J Clin Oncol
PY  - 2006
VL  - 24
SP  - 1990
EP  - 1996
ER  - 
TY  - JOUR
LB  - 60.
AU  - Pollack, A
AU  - Zagars, GK
AU  - Starkschall, G
AU  - Antolak, JA
AU  - Lee, JJ
AU  - Huang, E
TI  - Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial
J2  - Int J Radiat Oncol Biol Phys
PY  - 2002
VL  - 53
SP  - 1097
EP  - 1105
ER  - 
TY  - JOUR
LB  - 61.
AU  - Zietman, ALD
AU  - DeSilvio, ML
AU  - Slater, JD
AU  - Rossi, CJ, Jr
AU  - Miller, DW
AU  - Adams, JA
TI  - Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial
J2  - JAMA
PY  - 2005
VL  - 294
SP  - 1233
EP  - 1239
ER  - 
TY  - JOUR
LB  - 62.
AU  - Dearnaley, DP
AU  - Sydes, MR
AU  - Graham, JD
AU  - Aird, EG
AU  - Cowan, RA
AU  - Huddart, RA
TI  - Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial
J2  - Lancet Oncol
PY  - 2007
VL  - 8
SP  - 475
EP  - 487
ER  - 
TY  - JOUR
LB  - 63.
AU  - Kuban, DA
AU  - Tucker, SL
AU  - Dong, L
AU  - Starkschall, G
AU  - Huang, EH
AU  - Cheung, MR
TI  - Long-Term Results of the MD. Anderson Randomized Dose-Escalation Trial for Prostate Cancer
J2  - Int J Radiat Oncol Biol Phys
PY  - 2008
VL  - 70
SP  - 67
EP  - 74
ER  - 
TY  - ELEC
LB  - 64.
AU  - Pearson, SD
AU  - Ladapo, J
AU  - Prosser, L
TI  - Intensity modulated radiation therapy (IMRT) for localized prostate cancer
PY  - 2007
UR  - www.icer-review.org/index.php/imrt.html
M1  - July 2009
ER  - 
TY  - JOUR
LB  - 65.
AU  - Viani, GA
AU  - Stefano, EJ
AU  - Afonso, SL
TI  - Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials
J2  - Int J Radiat Oncol Biol Phys
PY  - 2009
VL  - 74
SP  - 1405
EP  - 1418
ER  - 
TY  - JOUR
LB  - 66.
AU  - Vargas, C
AU  - Martinez, A
AU  - Kestin, LL
AU  - Yan, D
AU  - Grills, I
AU  - Brabbins, DS
TI  - Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy
J2  - Int J Radiat Oncol Biol Phys
PY  - 2005
VL  - 62
SP  - 1297
EP  - 1308
ER  - 
TY  - JOUR
LB  - 67.
AU  - Koper, PC
AU  - Heemsbergen, WD
AU  - Hoogeman, MS
AU  - Jansen, PP
AU  - Hart, GA
AU  - Wijnmaalen, AJ
TI  - Impact of volume and location of irradiated rectum wall on rectal blood loss after radiotherapy of prostate cancer
J2  - Int J Radiat Oncol Biol Phys
PY  - 2004
VL  - 58
SP  - 1072
EP  - 1082
ER  - 
TY  - JOUR
LB  - 68.
AU  - Bui, C
AU  - Glassburn, J
TI  - IMRT for prostate cancer: Improving the therapeutic ratio
J2  - Comm Oncol
PY  - 2006
VL  - 3
SP  - 659
EP  - 661
ER  - 
TY  - JOUR
LB  - 69.
AU  - Donovan, E
AU  - Bleakley, N
AU  - Denholm, E
AU  - Evans, P
AU  - Gothard, L
AU  - Hanson, J
TI  - Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy
J2  - Radiother Oncol
PY  - 2007
VL  - 82
SP  - 254
EP  - 264
ER  - 
TY  - JOUR
LB  - 70.
AU  - Pignol, J
AU  - Olivotto, I
AU  - Rakovitch, E
AU  - Gardner, S
AU  - Ackerman, I
AU  - Sixel, K
TI  - Phase III randomized study of intensity modulated radiation therapy versus standard wedging technique for adjuvant breast radiotherapy
J2  - Int J Radiat Oncol Biol Phys
PY  - 2006
VL  - 66
IS  - Suppl.
SP  - S1
ER  - 
TY  - JOUR
LB  - 71.
AU  - Pow, EH
AU  - Kwong, DL
AU  - McMillan, AS
AU  - Wong, MC
AU  - Sham, JS
AU  - Leung, LH
TI  - Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: Initial report on a randomized controlled clinical trial
J2  - Int J Radiat Oncol Biol Phys
PY  - 2006
VL  - 66
SP  - 981
EP  - 991
ER  - 
TY  - JOUR
LB  - 72.
AU  - Kam, MK
AU  - Leung, SF
AU  - Zee, B
AU  - Choi, PHK
AU  - Chau, RMC
AU  - Cheung, KY
TI  - Impact of intensity-modulated radiotherapy (IMRT) on salivary gland function in early-stage nasopharyngeal carcinoma (NPC) patients: A prospective randomized study
J2  - J Clin Oncol
PY  - 2005
VL  - 23
SP  - S500
ER  - 
TY  - JOUR
LB  - 73.
AU  - Nutting, C
TI  - First results of a phase III multicenter randomized controlled trial of intensity modulated (IMRT) versus conventional radiotherapy (RT) in head and neck cancer
J2  - J Clin Oncol
PY  - 2009
VL  - 27
IS  - Suppl. 18
SP  - LBA6006
ER  - 
TY  - ELEC
LB  - 74.
AU  - Cancer Research UK
TI  - External radiotherapy for prostate cancer
PY  - 2007
UR  - www.cancerhelp.org.uk/help/default.asp?page=2881
M1  - June 2009
ER  - 
TY  - JOUR
LB  - 75.
AU  - Baker, CR
AU  - Hardy, V
TI  - Provision of IMRT in the UK. Part 2. Current levels, planned expansion and obstacles to implementation
J2  - J Radiother Pract
PY  - 2003
VL  - 3
SP  - 181
EP  - 184
ER  - 
TY  - JOUR
LB  - 76.
AU  - Jefferies, S
AU  - Taylor, A
AU  - Reznek, R
TI  - Results of a national survey of radiotherapy planning and delivery in the UK in 2007
J2  - Clin Oncol
PY  - 2009
VL  - 21
SP  - 204
EP  - 217
ER  - 
TY  - JOUR
LB  - 77.
AU  - Marchal, C
AU  - Lapeyre, M
AU  - Beckendorf, V
AU  - Aletti, P
AU  - Hasle, E
AU  - Dubois, JB
TI  - Preliminary results of the assessment of intensity modulated radiotherapy (IMRT) for prostatic and head and neck tumors (STIC 2001)
J2  - Cancer Radiother
PY  - 2004
VL  - 8
IS  - Suppl. 1
SP  - 121
EP  - 127
ER  - 
TY  - JOUR
LB  - 78.
AU  - Konski, A
AU  - Watkins-Bruner, D
AU  - Feigenberg, S
AU  - Hanlon, A
AU  - Kulkarni, S
AU  - Beck, J
TI  - Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer
J2  - Int J Radiat Oncol Biol Phys
PY  - 2006
VL  - 66
SP  - 408
EP  - 415
ER  - 
TY  - JOUR
LB  - 79.
AU  - Van de Werf, E
AU  - Lievens, Y
AU  - Verstraete, J
AU  - Pauwels, K
AU  - Van den Bogaert, W
TI  - Time and motion study of radiotherapy delivery: Economic burden of increased quality assurance and IMRT
J2  - Radiother Oncol
PY  - 2009
VL  - 93
SP  - 137
EP  - 140
ER  - 
TY  - JOUR
LB  - 80.
AU  - Miles, EA
AU  - Clark, CH
AU  - Urbano, MT
AU  - Bidmead, M
AU  - Dearnaley, DP
AU  - Harrington, KJ
TI  - The impact of introducing intensity modulated radiotherapy into routine clinical practice
J2  - Radiother Oncol
PY  - 2005
VL  - 77
SP  - 241
EP  - 246
ER  - 
TY  - JOUR
LB  - 81.
AU  - Bonastre, J
AU  - Noel, E
AU  - Chevalier, J
AU  - Gerard, JP
AU  - Lefkopoulos, D
AU  - Bourhis, J
TI  - Implications of learning effects for hospital costs of new health technologies: the case of intensity modulated radiation therapy
J2  - Int J Technol Assess Health Care
PY  - 2007
VL  - 23
SP  - 248
EP  - 254
ER  - 
TY  - JOUR
LB  - 82.
AU  - Van der Werf, E
AU  - Lievens, Y
AU  - Verstraete, J
AU  - Pauwels, K
AU  - Van den Bogaert, W
TI  - Time and motion study of radiotherapy delivery: Economic burden of increased quality assurance and IMRT
J2  - Radiother Oncol
PY  - 2009
VL  - 93
SP  - 137
EP  - 140
ER  - 
TY  - JOUR
LB  - 83.
AU  - Downs, SH
AU  - Black, N
TI  - The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions
J2  - J Epidemiol Community Health
PY  - 1998
VL  - 52
SP  - 377
EP  - 384
ER  - 
TY  - JOUR
LB  - 84.
AU  - Kupelian, PA
AU  - Reddy, CA
AU  - Carlson, TP
AU  - Altsman, KA
AU  - Willoughby, TR
TI  - Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer
J2  - Int J Radiat Oncol Biol Phys
PY  - 2002
VL  - 53
SP  - 904
EP  - 912
ER  - 
TY  - JOUR
LB  - 85.
AU  - Kupelian, PA
AU  - Thakka, VV
AU  - Khuntia, D
AU  - Reddy, CA
AU  - Klein, EA
AU  - Mahadevan, A
TI  - Hypofractionated intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: Long-term outcomes
J2  - Int J Radiat Oncol Biol Phys
PY  - 2005
VL  - 63
SP  - 1463
EP  - 1468
ER  - 
TY  - JOUR
LB  - 86.
AU  - Kupelian, PA
AU  - Willoughby, TR
AU  - Reddy, CA
AU  - Klein, EA
AU  - Mahadevan, A
TI  - Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience
J2  - Int J Radiat Oncol Biol Phys
PY  - 2007
VL  - 68
SP  - 1424
EP  - 1430
ER  - 
TY  - JOUR
LB  - 87.
AU  - Reddy, C
AU  - Mahadevan, A
AU  - Klein, E
AU  - Willoughby, T
AU  - Kupelian, P
TI  - Hypofractionated intensity modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer
J2  - Int J Radiat Oncol Biol Phys
PY  - 2006
VL  - 66
SP  - 1053
EP  - 1058
ER  - 
TY  - JOUR
LB  - 88.
AU  - Sanguineti, G
AU  - Cavey, ML
AU  - Endres, EJ
AU  - Franzone, P
AU  - Barra, S
AU  - Parker, BC
TI  - Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate only radiotherapy to 76 Gy?
J2  - Strahlenther Onkol
PY  - 2006
VL  - 182
SP  - 543
EP  - 549
ER  - 
TY  - JOUR
LB  - 89.
AU  - Vora, SA
AU  - Wong, WW
AU  - Schild, SE
AU  - Ezzell, GA
AU  - Halyard, MY
TI  - Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer
J2  - Int J Radiat Oncol Biol Phys
PY  - 2007
VL  - 68
SP  - 1053
EP  - 1058
ER  - 
TY  - JOUR
LB  - 90.
AU  - Vora, S
AU  - Wong, W
AU  - Schild, S
AU  - Ezzell, G
AU  - Halyard, M
TI  - Analysis of biochemical control and prognostic factors in patients treated with either low dose 3-dimensional conformal radiation therapy or high dose IMRT for localized prostate cancer
J2  - Int J Radiat Oncol Biol Phys
PY  - 2006
VL  - 66
SP  - S370
ER  - 
TY  - JOUR
LB  - 91.
AU  - Zelefsky, MJ
AU  - Levin, EJ
AU  - Hunt, M
AU  - Yamada, Y
AU  - Shippy, AM
AU  - Jackson, A
TI  - Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer
J2  - Int J Radiat Oncol Biol Phys
PY  - 2008
VL  - 70
SP  - 1124
EP  - 1129
ER  - 
TY  - JOUR
LB  - 92.
AU  - Zelefsky, MJ
TI  - High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients
J2  - Int J Radiat Oncol Biol Phys
PY  - 2002
VL  - 53
SP  - 1111
EP  - 1116
ER  - 
TY  - JOUR
LB  - 93.
AU  - Zelefsky, MJ
AU  - Fuks, Z
AU  - Happersett, L
AU  - Lee, HJ
AU  - Ling, CC
AU  - Burman, CM
TI  - Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer
J2  - Radiother Oncol
PY  - 2000
VL  - 55
SP  - 241
EP  - 249
ER  - 
TY  - JOUR
LB  - 94.
AU  - Zelefsky, MJ
AU  - Marion, C
AU  - Fuks, Z
AU  - Leibel, SA
TI  - Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy
J2  - J Urol
PY  - 2003
VL  - 170
SP  - 1828
EP  - 1832
ER  - 
TY  - JOUR
LB  - 95.
AU  - Zelefsky, MJ
AU  - Chan, H
AU  - Hunt, M
AU  - Yamada, Y
AU  - Shippy, AM
AU  - Amols, H
TI  - Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer
J2  - J Urol
PY  - 2006
VL  - 176
SP  - 1415
EP  - 1419
ER  - 
TY  - JOUR
LB  - 96.
AU  - Zelefsky, MJ
AU  - Leibel, SA
AU  - Gaudin, PB
AU  - Kutcher, GJ
AU  - Fleshner, NE
AU  - Venkatramen, ES
TI  - Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer
J2  - Int J Radiat Oncol Biol Phys
PY  - 1998
VL  - 41
SP  - 491
EP  - 500
ER  - 
TY  - JOUR
LB  - 97.
AU  - Burman, C
AU  - Chui, CS
AU  - Kutcher, G
AU  - Leibel, S
AU  - Zelefsky, M
AU  - LoSasso, T
TI  - Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: a strategy for large-scale implementation for the treatment of carcinoma of the prostate
J2  - Int J Radiat Oncol Biol Phys
PY  - 1997
VL  - 39
SP  - 863
EP  - 873
ER  - 
TY  - JOUR
LB  - 98.
AU  - Zelefsky, MJ
AU  - Yamada, Y
AU  - Fuks, Z
AU  - Zhang, ZG
AU  - Hunt, M
AU  - Cahlon, O
TI  - Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes
J2  - Int J Radiat Oncol Biol Phys
PY  - 2008
VL  - 71
SP  - 1028
EP  - 1033
ER  - 
TY  - JOUR
LB  - 99.
AU  - Cahlon, O
AU  - Zelefsky, MJ
AU  - Shippy, A
AU  - Chan, H
AU  - Fuks, Z
AU  - Yamada, Y
TI  - Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: Toxicity and biochemical outcomes
J2  - Int J Radiat Oncol Biol Phys
PY  - 2008
VL  - 71
SP  - 330
EP  - 337
ER  - 
TY  - JOUR
LB  - 100.
AU  - Ashman, JB
AU  - Zelefsky, MJ
AU  - Hunt, MS
AU  - Leibel, SA
AU  - Fuks, Z
TI  - Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy
J2  - Int J Radiat Oncol Biol Phys
PY  - 2005
VL  - 63
SP  - 765
EP  - 771
ER  - 
TY  - JOUR
LB  - 101.
AU  - Mast, M
AU  - Wiggenraad, R
AU  - Struikmans, H
TI  - IMRT, what have we learned?
J2  - ESTRO 25 Leipzig Duitsland
PY  - 2006
SP  - S121
ER  - 
TY  - ELEC
LB  - 102.
AU  - Mast, M
AU  - Wiggenraad, R
AU  - Struikmans, H
TI  - IMRT, what have we learned? A systematic review in prostate cancer
PY  - 2009
UR  - www.oncozone.net/uploads/pdf/385adbbbcf279060019714f3aa5ad2f7.pdf
M1  - July 2009
ER  - 
TY  - JOUR
LB  - 103.
AU  - Dehnad, H
AU  - Nederveen, AJ
AU  - van der Heide, UA
AU  - van Moorselaar, RJ
AU  - Hofman, P
AU  - Lagendijk, JJ
TI  - Clinical feasibility study for the use of implanted gold seeds in the prostate as reliable positioning markers during megavoltage irradiation
J2  - Radiother Oncol
PY  - 2003
VL  - 67
SP  - 295
EP  - 302
ER  - 
TY  - JOUR
LB  - 104.
AU  - Van Vulpen, M
AU  - De Leeuw, JR
AU  - Van Gellekom, MP
AU  - Van Der Hoeven, J
AU  - De Graeff, A
AU  - Van Moorselaar, RJ
TI  - A prospective quality of life study in patients with locally advanced prostate cancer, treated with radiotherapy with or without regional or interstitial hyperthermia
J2  - Int J Hyperthermia
PY  - 2003
VL  - 19
SP  - 402
EP  - 413
ER  - 
TY  - JOUR
LB  - 105.
AU  - Kirichenko, AV
AU  - Ruth, K
AU  - Horwitz, E
AU  - Buyyounouski, M
AU  - Feigenberg, S
AU  - Chen, D
TI  - Intensity modulated radiation therapy for prostate cancer: Preliminary results on treatment morbidity compared to 3-D conformal radiation therapy
J2  - Int J Radiat Oncol Biol Phys
PY  - 2006
VL  - 66
SP  - S326
ER  - 
TY  - JOUR
LB  - 106.
AU  - Sharma, N
AU  - Li, T
AU  - Horwitz, E
AU  - Pollack, A
AU  - Buyyounouski, M
TI  - Intensity modulated radiation therapy reduces gastrointestinal morbidity in patients treated with androgen deprivation therapy for prostate cancer
J2  - Int J Radiat Oncol Biol Phys
PY  - 2007
VL  - 69
SP  - S10
ER  - 
TY  - JOUR
LB  - 107.
AU  - Morgan, P
AU  - Ruth, K
AU  - Horwitz, E
AU  - Buyyounouski, M
AU  - Uzzo, R
TI  - A matched pair comparison of intensity modulated radiotherapy and three-dimensional conformal radiotherapy for prostate cancer: Toxicity and outcomes
J2  - Int J Radiat Oncol Biol Phys
PY  - 2007
VL  - 69
SP  - S393
ER  - 
TY  - JOUR
LB  - 108.
AU  - Boehmer, D
AU  - Herschel, R
AU  - Badakhshi, H
AU  - Eichwurzel, I
AU  - Wernecke, K
AU  - Budach, V
TI  - Matched pair analysis of patients with prostate cancer treated with IMRT or 3-D conformal radiotherapy
J2  - Int J Radiat Oncol Biol Phys
PY  - 2006
VL  - 66
IS  - Suppl. 1
SP  - 394
ER  - 
TY  - ELEC
LB  - 109.
AU  - Boehmer, D
TI  - Matched pair analysis of patients with prostate cancer treated with imrt or 3-d conformal radiotherapy
PY  - 2007
UR  - www.oncozone.net/en/poster/show/id/167
M1  - June 2009
ER  - 
TY  - JOUR
LB  - 110.
AU  - Martinez, A
AU  - Yan, D
AU  - Brabbins, D
AU  - Kestin, L
AU  - Mitchell, C
AU  - Wallace, M
TI  - Acute and chronic toxicity of adaptive image guided radiation therapy (A-IGRT) delivered with 3D-conformal technique (3D-CRT) vs. intensity modulation (IMRT) in 728 prostate cancer patients
J2  - Int J Radiat Oncol Biol Phys
PY  - 2007
VL  - 69
SP  - S317
ER  - 
TY  - JOUR
LB  - 111.
AU  - Kupelian, P
AU  - Thames, H
AU  - Levy, L
AU  - Horwitz, E
AU  - Martinez, A
AU  - Michalski, J
TI  - Year of treatment as an independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era
J2  - Int J Radiat Oncol Biol Phys
PY  - 2005
VL  - 63
SP  - 795
EP  - 799
ER  - 
TY  - JOUR
LB  - 112.
AU  - Shrerer, RW
AU  - Langenberg, P
AU  - von Elm, E
TI  - Full publication results published in abstracts
J2  - Cochrane Database Methodol Rev
PY  - 2005
VL  - 2
ER  - 
TY  - JOUR
LB  - 113.
AU  - Konski, A
AU  - Watkins-Bruner, D
AU  - Feigenberg, S
AU  - Hanlon, A
AU  - Kulkarni, S
AU  - Beck, J
TI  - Intensity modulated radiation therapy (IMRT) is a cost-effective treatment for intermediate risk prostate cancer
J2  - Int J Radiat Oncol Biol Phys
PY  - 2004
VL  - 60
SP  - S144
ER  - 
TY  - JOUR
LB  - 114.
AU  - Konski, A
TI  - Cost-effectiveness of intensity-modulated radiation therapy
J2  - Expert Rev Pharmacoecon Outcomes Res
PY  - 2005
VL  - 5
SP  - 137
EP  - 140
ER  - 
TY  - JOUR
LB  - 115.
AU  - Remonnay, R
AU  - Pommier, P
AU  - Lapeyre, M
AU  - Hay, M
AU  - Maingon, P
AU  - Bensadoun, R
TI  - Cost comparison between standard 3D conformal radiotherapy (CRT) and intensity modulated radiotherapy (IMRT) for prostate cancer: Results of a multicenter prospective medico-economic study in 8 anticancer centers
J2  - Int J Radiat Oncol Biol Phys
PY  - 2005
VL  - 63
SP  - S188
EP  - S189
ER  - 
TY  - JOUR
LB  - 116.
AU  - Shimizu, F
AU  - Fujino, K
AU  - Ito, YM
AU  - Fukuda, T
AU  - Kawachi, Y
AU  - Minowada, S
TI  - Fujino Factors associated with variation in utility scores among patients with prostate cancer
J2  - Value Health
PY  - 2008
VL  - 11
SP  - 1190
EP  - 1193
ER  - 
TY  - JOUR
LB  - 117.
AU  - van Tol-Geerdink, JJ
AU  - Stalmeier, PF
AU  - Pasker-de Jong, PC
AU  - Huizenga, H
AU  - van Lin, EN
AU  - Schimmel, EC
TI  - Systematic review of the effect of radiation dose on tumor control and morbidity in the treatment of prostate cancer by 3D-CRT
J2  - Int J Radiat Oncol Biol Phys
PY  - 2006
VL  - 64
SP  - 534
EP  - 543
ER  - 
TY  - JOUR
LB  - 118.
AU  - Gulliford, SL
AU  - Foo, K
AU  - Morgan, RC
AU  - Aird, EG
AU  - Bidmead, AM
AU  - Critchley, H
TI  - Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: Evidence from MRC RT01 Trial ISRCTN 47772397
J2  - Int J Radiat Oncol Biol Phys
PY  - 2009
VL  - 76
SP  - 747
EP  - 754
ER  - 
TY  - JOUR
LB  - 119.
AU  - Kestin, LL
AU  - Vicini, FA
AU  - Martinez, AA
TI  - Practical application of biochemical failure definitions: what to do and when to do it
J2  - Int J Radiat Oncol Biol Phys
PY  - 2002
VL  - 53
SP  - 304
EP  - 315
ER  - 
TY  - JOUR
LB  - 120.
AU  - Collins, R
AU  - Fenwick, E
AU  - Trowman, R
AU  - Perard, R
AU  - Norman, G
AU  - Light, K
TI  - A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer
J2  - Health Technol Assess
PY  - 2007
VL  - 11
IS  - 2
ER  - 
TY  - ELEC
LB  - 121.
AU  - Office for National Statistics
TI  - Interim life tables. Expectation of life United Kingdom males
PY  - 2009
UR  - www.gad.gov.uk/Demography%20Data/Life%20Tables/Interim_life_tables.html
M1  - June 2009
ER  - 
TY  - ELEC
LB  - 122.
AU  - NICE
TI  - Guide to the methods of technology appraisal
PY  - 2008
UR  - www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf
M1  - May 2009
ER  - 
TY  - JOUR
LB  - 123.
AU  - Korfage, IJ
AU  - Essink-Bot, ML
AU  - Borsboom, GJ
AU  - Madalinska, JB
AU  - Kirkels, WJ
AU  - Habbema, JD
TI  - Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer
J2  - Int J Cancer
PY  - 2005
VL  - 116
SP  - 291
EP  - 296
ER  - 
TY  - JOUR
LB  - 124.
AU  - Pickard, AS
AU  - Lin, HW
AU  - Knight, SL
AU  - Sharifi, R
AU  - Wu, Z
AU  - Hung, SY
TI  - Proxy assessment of health-related quality of life in african american and white respondents with prostate cancer: perspective matters
J2  - Med Care
PY  - 2009
VL  - 47
SP  - 176
EP  - 183
ER  - 
TY  - JOUR
LB  - 125.
AU  - Sullivan, PW
AU  - Mulani, PM
AU  - Fishman, M
AU  - Sleep, D
TI  - Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer
J2  - Qual Life Res
PY  - 2007
VL  - 16
SP  - 571
EP  - 575
ER  - 
TY  - BOOK
LB  - 126.
AU  - Ara, R
AU  - Brazier, J
TI  - Health related quality of life by age, gender and history of cardiovascular disease: results from the Health Survey for England
UR  - www.shef.ac.uk/content/1/c6/01/87/47/HEDS%20DP%2009-12.pdf
Y2  - September 2009
PB  - The University of Sheffield
PY  - 2009
ER  - 
TY  - BOOK
LB  - 127.
AU  - Curtis, L
TI  - Unit costs of health and social care
CY  - Canterbury
PB  - PSSRU
PY  - 2008
ER  - 
TY  - GEN
LB  - 128.
AU  - British Medical Association and Royal Pharmaceutical Society of Great Britain
TI  - British national formulary
CY  - London
PB  - BMA and RPS
PY  - 2007
ER  - 
TY  - GEN
LB  - 129.
AU  - NICE
TI  - Docetaxel for the treatment of hormone-refractory metastatic prostate cancer
PY  - 2006
SP  - 1
EP  - 35
ER  - 
TY  - JOUR
LB  - 130.
AU  - Claxton, K
AU  - Sculpher, M
AU  - McCabe, C
AU  - Briggs, A
AU  - Akehurst, RL
AU  - Buxton, M
TI  - Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra
J2  - Health Econ
PY  - 2005
VL  - 14
SP  - 339
EP  - 347
ER  - 
TY  - JOUR
LB  - 131.
AU  - Konski, A
AU  - Watkins-Bruner, D
AU  - Feigenberg, S
AU  - Hanlon, A
AU  - Kulkarni, S
AU  - Beck, JR
TI  - Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer
J2  - Int J Radiat Oncol Biol Phys
PY  - 2006
VL  - 66
SP  - 408
EP  - 415
ER  - 
TY  - RPRT
LB  - 132.
AU  - National Radiotherapy Advisory Groug (NRAG)
TI  - Advice to NRAG radiotherapy provision in England. A report from the National Radiotherapy Advisory Group – workforce subgroup
PB  - NRAG
PY  - 2006
ER  - 
TY  - JOUR
LB  - 133.
AU  - Egger, M
TI  - How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study
J2  - Health Technol Assess
PY  - 2003
VL  - 7
IS  - 1
ER  - 
TY  - JOUR
LB  - 134.
AU  - Moher, D
AU  - Pham, B
AU  - Klassen, TP
AU  - Schulz, KF
AU  - Berlin, JA
AU  - Jadad, AR
TI  - What contributions do languages other than English make on the results of meta-analyses?
J2  - J Clin Epidemiol
PY  - 2000
VL  - 53
SP  - 964
EP  - 972
ER  - 
TY  - JOUR
LB  - 135.
AU  - Pham,, B
AU  - Klassen, TP
AU  - Lawson, ML
AU  - Moher, D
TI  - Language of publication restrictions in systematic reviews gave different results depending on whether the intervention was conventional or complementary
J2  - J Clin Epidemiol
PY  - 2005
VL  - 58
SP  - 769
EP  - 776
ER  - 
TY  - JOUR
LB  - 136.
AU  - Collette, L
AU  - Burzykowski, T
AU  - Schroder, FH
TI  - Prostate-specific antigen (PSA) alone is not an appropriate surrogate market of long-term therapeutic benefit in prostate cancer trials
J2  - Eur J Cancer
PY  - 2006
VL  - 42
SP  - 1344
EP  - 1350
ER  - 
TY  - ELEC
LB  - 137.
AU  - Current Controlled Trials
TI  - A randomised phase III multi-centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer
PY  - 2010
UR  - www.controlled-trials.com/mrct/trial/487683
M1  - May 2009
ER  - 
TY  - JOUR
LB  - 138.
AU  - Adkison, JB
AU  - Patel, RR
AU  - Bentzen, SM
AU  - Hong, TS
AU  - McHaffie, DR
AU  - Ritter, MA
TI  - Pelvic nodal dose escalation in conjunction with hypofractionated IMRT for high risk prostate cancer
J2  - Int J Radiat Oncol Biol Phys
PY  - 2008
VL  - 72
SP  - S305
ER  - 
TY  - JOUR
LB  - 139.
AU  - Allison, RR
AU  - Murphy, G
AU  - Gay, H
AU  - Arastu, H
AU  - Frelix, G
AU  - Sibata, C
TI  - Daily CT on rails IGRT for post-prostatectomy rising PSA: outcomes and morbidity
J2  - Int J Radiat Oncol Biol Phys
PY  - 2008
VL  - 72
SP  - S346
ER  - 
TY  - JOUR
LB  - 140.
AU  - Amer, AM
AU  - Mott, J
AU  - Mackay, RI
AU  - Williams, PC
AU  - Livsey, J
AU  - Logue, JP
TI  - Prediction of the benefits from dose-escalated hypofractionated intensity-modulated radiotherapy for prostate cancer
J2  - Int J Radiat Oncol Biol Phys
PY  - 2003
VL  - 56
SP  - 199
EP  - 207
ER  - 
TY  - JOUR
LB  - 141.
AU  - Bernard, JR
AU  - Buskirk, SJ
AU  - Serago, C
AU  - Ko, SJ
AU  - Kim, S
AU  - Casale, HE
TI  - Evaluation of genitourinary side effects following image guided intensity modulated radiation therapy to the prostate
J2  - Int J Radiat Oncol Biol Phys
PY  - 2008
VL  - 72
IS  - Suppl. 1
SP  - 330
ER  - 
TY  - JOUR
LB  - 142.
AU  - Bossi, A
TI  - Modern External-Beam Radiation Therapy for Prostate Cancer: How and When?
J2  - Eur Urol
PY  - 2008
VL  - 7
SP  - S22
EP  - S28
ER  - 
TY  - JOUR
LB  - 143.
AU  - Bhatnagar, A
AU  - Heron, D
AU  - Beriwal, S
AU  - Flickinger, J
AU  - Smith, R
AU  - Deutsch, M
TI  - Inital outcomes results for large multi-center integrated cancer network for the treatment of prostate cancer with IMRT
J2  - Int J Radiat Oncol Biol Phys
PY  - 2006
VL  - 66
IS  - Suppl. 1
SP  - S69
ER  - 
TY  - JOUR
LB  - 144.
AU  - Buyyounouski, M
AU  - Li, T
AU  - Watkins-Bruner, D
AU  - Horwitz, E
AU  - Pollack, A
TI  - A comparison of sexual function following radiotherapy for prostate cancer: Results of a prospective, randomized trial of hypofractionated intensity modulated radiotherapy
J2  - Int J Radiat Oncol Biol Phys
PY  - 2007
VL  - 69
SP  - S7
EP  - S8
ER  - 
TY  - JOUR
LB  - 145.
AU  - Catton, C
AU  - Chung, P
AU  - Haycocks, T
AU  - Warde, P
AU  - Alasti, H
AU  - Bayley, A
TI  - Hypofractionated intensity modulated radiation therapy for prostate cancer
J2  - Int J Radiat Oncol Biol Phys
PY  - 2002
VL  - 54
SP  - 188
ER  - 
TY  - JOUR
LB  - 146.
AU  - Chan, HM
AU  - Zelefsky, MJ
AU  - Fuks, Z
AU  - Hunt, M
AU  - Ling, C
AU  - Leibel, SA
TI  - Long-term outcome of high dose intensity modulated radiotherapy for clinically localized prostate cancer
J2  - Int J Radiat Oncol Biol Phys
PY  - 2004
VL  - 60
IS  - Suppl. 1
SP  - S169
EP  - S170
ER  - 
TY  - JOUR
LB  - 147.
AU  - Chao, S
AU  - Reddy, C
AU  - Thakkar, VV
AU  - Kupelian, P
AU  - Djemil, T
AU  - Mahadevan, A
TI  - Impact of high-dose radiation on erectile function in patients treated with intensity-modulated radiation therapy for prostate cancer
J2  - Int J Radiat Oncol Biol Phys
PY  - 2004
VL  - 60
SP  - S270
EP  - S271
ER  - 
TY  - JOUR
LB  - 148.
AU  - Cheung, P
AU  - Loblaw, D
AU  - Morton, G
AU  - Zhang, L
AU  - Basran, P
AU  - Tirona, R
TI  - Acute toxicity in high risk prostate cancer patients after elective nodal irradiation using IMRT: Comparison to a 4 field technique
J2  - Int J Radiat Oncol Biol Phys
PY  - 2008
VL  - 72
SP  - S291
EP  - S292
ER  - 
TY  - JOUR
LB  - 149.
AU  - Cohen, K
AU  - Teh, B
AU  - Mai, W
AU  - Paulino, A
AU  - Miles, B
AU  - Kadmon, D
TI  - Erectile function after nerve-sparing prostatectomy and intensity modulated radiotherapy for prostate cancer patients
J2  - Int J Radiat Oncol Biol Phys
PY  - 2006
VL  - 66
SP  - S130
ER  - 
TY  - JOUR
LB  - 150.
AU  - Daly, T
AU  - Hickey, BE
AU  - Lehman, M
AU  - Francis, DP
TI  - Adjuvant radiotherapy following radical prostatectomy for prostate cancer
J2  - Cochrane Database Syst Rev
PY  - 2008
VL  - 4
ER  - 
TY  - JOUR
LB  - 151.
AU  - Dearnaley, DP
AU  - Khoo, VS
AU  - Norman, AR
AU  - Meyer, L
AU  - Nahum, A
AU  - Yarnold, J
TI  - Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer; a randomised trial
J2  - Lancet
PY  - 1999
VL  - 353
SP  - 267
EP  - 272
ER  - 
TY  - JOUR
LB  - 152.
AU  - De Meerleer, G
AU  - Fonteyne, V
AU  - Meersschout, S
AU  - Van den Broecke, C
AU  - Villeirs, G
AU  - Lumen, N
TI  - Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy
J2  - Radiother Oncol
PY  - 2008
VL  - 89
SP  - 205
EP  - 213
ER  - 
TY  - JOUR
LB  - 153.
AU  - Djemil, T
AU  - Reddy, C
AU  - Willoughby, T
AU  - Kupelian, P
TI  - Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer
J2  - Int J Radiat Oncol Biol Phys
PY  - 2003
VL  - 57
SP  - S275
EP  - S276
ER  - 
TY  - JOUR
LB  - 154.
AU  - Dogan, N
AU  - Wu, Y
AU  - Hagan, M
TI  - Simultaneous-integrated boost (SIB) IMRT for treatment of intermediate-risk prostate cancer with nodal irradiation
J2  - Int J Radiat Oncol Biol Phys
PY  - 2006
VL  - 66
IS  - Suppl. 1
SP  - 661
ER  - 
TY  - JOUR
LB  - 155.
AU  - Dogan, N
AU  - Siebers, JV
AU  - Keall, P
TI  - Clinical comparison of head and neck and prostate IMRT plans using absorbed dose to medium and absorbed dose to water
J2  - Phys Med Biol
PY  - 2006
VL  - 51
SP  - 4967
EP  - 4980
ER  - 
TY  - JOUR
LB  - 156.
AU  - Dong, L
AU  - O’Daniel, J
AU  - Smith, L
AU  - Kuban, D
AU  - Bounds, S
AU  - Rosen, I
TI  - Comparison of 3D conformal and intensity-modulated radiation therapy for early-stage prostate cancer
J2  - Int J Radiat Oncol Biol Phys
PY  - 2001
VL  - 51
IS  - Suppl. 1
SP  - 320
ER  - 
TY  - BOOK
LB  - 157.
AU  - Debus, J
AU  - Zierhut, D
AU  - Didinger, B
AU  - Schlegel, W
AU  - Wannenmacher, M
TI  - Inverse planning and intensity-modulated radiotherapy in patients with prostate cancer
CY  - Basel
PB  - S. Karger Publishers Inc.
PY  - 2002
SP  - 25
EP  - 34
ER  - 
TY  - JOUR
LB  - 158.
AU  - Engler, MJ
AU  - Tsai, JS
AU  - Vora, S
AU  - Wazer, DE
AU  - DiPetrillo, T
TI  - Application of dynamic intensity-modulated radiation therapy to the treatment of prostate cancer
J2  - Int J Radiat Oncol Biol Phys
PY  - 1997
VL  - 39
IS  - Suppl. 2
SP  - 193
ER  - 
TY  - JOUR
LB  - 159.
AU  - Fonteyne, V
AU  - Vakaet, L
AU  - Villeirs, G
AU  - Oosterlinck, W
AU  - Denoyette, L
AU  - De Neve, W
TI  - Intensity-modulated radiotherapy (IMRT) for prostate cancer at Ghent university hospital (GUH): First report on late toxicity
J2  - Eur Urol Suppl
PY  - 2006
VL  - 5
SP  - 168
ER  - 
TY  - JOUR
LB  - 160.
AU  - Guckenberger, M
AU  - Goebel, J
AU  - Polat, B
AU  - Vordermark, D
AU  - Flentje, M
TI  - Acute toxicity after intensity-modulated, image guided radiation therapy of the prostate-carcinoma
J2  - Strahlenther Onkol
PY  - 2008
VL  - 184
SP  - 44
EP  - 45
ER  - 
TY  - JOUR
LB  - 161.
AU  - Guerrero Urbano, MT
AU  - Nutting, CM
TI  - Clinical use of intensity-modulated radiotherapy: part II
J2  - Br J Radiol
PY  - 2004
VL  - 77
SP  - 177
EP  - 182
ER  - 
TY  - JOUR
LB  - 162.
AU  - Hsi, R
AU  - Okura, T
AU  - Garver, E
AU  - Parsai, H
AU  - Cho, P
AU  - Jacobs, D
TI  - Acute toxicity results using dynamic intensity modulated radiotherapy (dIMRT) in high-risk prostate cancer
J2  - Int J Radiat Oncol Biol Phys
PY  - 2007
VL  - 69
SP  - S365
EP  - S366
ER  - 
TY  - JOUR
LB  - 163.
AU  - Johnstone, PAS
AU  - Williams, SR
AU  - Riffenburgh, RH
TI  - The 100-day PSA: usefulness as surrogate end point for biochemical disease-free survival after definitive radiotherapy of prostate cancer
J2  - Prostate Cancer Prostatic Dis
PY  - 2004
VL  - 7
SP  - 263
EP  - 267
ER  - 
TY  - ELEC
LB  - 164.
AU  - NIHR ProtecT
TI  - The ProtecT Trial – Evaluation the effectiveness of treatment for clinically localised prostate cancer
PY  - 2009
UR  - www.epi.bris.ac.uk/protect/
M1  - June 2009
ER  - 
TY  - JOUR
LB  - 165.
AU  - Lee, R
AU  - Chen, J
AU  - Sause, W
TI  - Image guided radiation therapy for prostate cancer using implanted fiducial markers with daily portal imaging
J2  - Int J Radiat Oncol Biol Phys
PY  - 2007
VL  - 69
SP  - S373
EP  - S374
ER  - 
TY  - JOUR
LB  - 166.
AU  - Liauw, S
AU  - Jani, A
AU  - Fricano, J
AU  - Rash, C
AU  - Pelizzari, C
AU  - Weichselbaum, R
TI  - Salvage RT for biochemical failure post-prostatectomy: Do we reduce or increase toxicity of treatment with IMRT?
J2  - Int J Radiat Oncol Biol Phys
PY  - 2007
VL  - 69
SP  - S337
EP  - S338
ER  - 
TY  - JOUR
LB  - 167.
AU  - Livi, L
AU  - Paiar, F
AU  - Banci-Buonamici, F
AU  - Simontacchi, G
AU  - Detti, B
AU  - Gacci, M
TI  - Localized prostate cancer treated with intensity-modulated radiotherapy
J2  - Tumori
PY  - 2006
VL  - 92
SP  - 197
EP  - 201
ER  - 
TY  - JOUR
LB  - 168.
AU  - Liu, YM
AU  - Shiau, CY
AU  - Lee, ML
AU  - Huang, PI
AU  - Hsieh, CM
AU  - Chen, PH
TI  - The role and strategy of IMRT in radiotherapy of pelvic tumors: dose escalation and critical organ sparing in prostate cancer
J2  - Int J Radiat Oncol Biol Phys
PY  - 2007
VL  - 67
SP  - 1113
EP  - 1123
ER  - 
TY  - JOUR
LB  - 169.
AU  - Khoo, VSD
TI  - Question of Dose, Fractionation and Technique: Ingredients for Testing Hypofractionation in Prostate Cancer – the CHHiP Trial
J2  - Clin Oncol
PY  - 2008
VL  - 20
SP  - 12
EP  - 14
ER  - 
TY  - JOUR
LB  - 170.
AU  - Kosakowski, J
AU  - Welzel, G
AU  - bo-Madyan, Y
AU  - Mai, S
AU  - Wertz, H
AU  - Wenz, F
TI  - Effectiveness and toxicity of the intensity modulated radiotherapy (IMRT) as hypofractionated boost with prostate carcinoma
J2  - Strahlenther Onkol
PY  - 2008
VL  - 184
SP  - 21
ER  - 
TY  - JOUR
LB  - 171.
AU  - Kry, S
AU  - Vassiliev, O
AU  - Kuban, D
AU  - Poenisch, F
AU  - Salehpour, M
AU  - Gillin, M
TI  - Prostate IMRT using unflattened beams
J2  - Int J Radiat Oncol Biol Phys
PY  - 2006
VL  - 66
SP  - S78
ER  - 
TY  - JOUR
LB  - 172.
AU  - Kuczer, D
AU  - Haidenberger, A
AU  - Pakisch, B
TI  - Is the compliance of the ICRU-62-guidelines possible in the high dose therapy of the prostate carcinoma? A comparison of 3D conformal techniques with IMRT
J2  - Strahlenther Onkol
PY  - 2008
VL  - 184
SP  - 101
EP  - 102
ER  - 
TY  - JOUR
LB  - 173.
AU  - Lim, TS
AU  - Cheung, PCF
AU  - Loblaw, DA
AU  - Morton, G
AU  - Sixel, KE
AU  - Pang, G
TI  - Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity result
J2  - Int J Radiat Oncol Biol Phys
PY  - 2008
VL  - 72
SP  - 85
EP  - 92
ER  - 
TY  - JOUR
LB  - 174.
AU  - Ma, C
AU  - Chi, Z
AU  - Xu, Q
AU  - Chen, L
AU  - Paskalev, K
AU  - Buyyounoski, M
TI  - Image guided adaptive radiotherapy of prostate cancer: a retrospective study
J2  - Int J Radiat Oncol Biol Phys
PY  - 2008
VL  - 72
SP  - S306
ER  - 
TY  - JOUR
LB  - 175.
AU  - Mahadevan, A
AU  - Manzoul, S
AU  - Reddy, C
TI  - IMRT to pelvic lymph nodes in prostate cancer
J2  - Int J Radiat Oncol Biol Phys
PY  - 2006
VL  - 66
SP  - S270
EP  - S275
ER  - 
TY  - JOUR
LB  - 176.
AU  - Marchand, V
AU  - Bourdin, S
AU  - Charbonnel, C
AU  - Rio, E
AU  - Munos, C
AU  - Campion, L
TI  - Health-related quality of life after 76 Gy intensity modulated radiotherapy for localized prostate cancer: A prospective and longitudinal study
J2  - Int J Radiat Oncol Biol Phys
PY  - 2008
VL  - 72
SP  - S102
ER  - 
TY  - JOUR
LB  - 177.
AU  - McCammon, R
AU  - Kavanagh, B
AU  - Newell, S
AU  - Raben, D
TI  - Acute toxicity assessment of a single institution series of prostate cancer patients treated with pelvic intensity modulated radiation therapy with synchronous integrated boost to the prostate or prostate bed
J2  - Int J Radiat Oncol Biol Phys
PY  - 2006
VL  - 66
SP  - S364
ER  - 
TY  - JOUR
LB  - 178.
AU  - McCloskey, S
AU  - Wollman, R
AU  - Rose, C
AU  - Ketting, C
AU  - Green, G
AU  - Ellerbroek, N
TI  - Quality of life (QOL) outcomes after three-dimensional conformal radiation therapy (3D-CRT) and intensity modulated radiation therapy (IMRT) for localized prostate cancer
J2  - Int J Radiat Oncol Biol Phys
PY  - 2005
VL  - 63
SP  - S113
ER  - 
TY  - JOUR
LB  - 179.
AU  - Melcon, I
AU  - Martin, C
AU  - Soria, P
AU  - Marques, E
AU  - Oviedo, A
AU  - Martin, M
TI  - Intensity modulated radiation therapy with ultrasound-based daily target localization for clinically localized prostate cancer: institutional experience and acute toxicity outcomes
J2  - EJC Suppl
PY  - 2007
VL  - 5
SP  - 297
ER  - 
TY  - JOUR
LB  - 180.
AU  - Michalski, JM
TI  - Radiation therapy in the management of locally advanced prostate cancer
J2  - Curr Urol Rep
PY  - 2006
VL  - 7
SP  - 217
EP  - 224
ER  - 
TY  - JOUR
LB  - 181.
AU  - Molla, M
AU  - Linero, D
AU  - Toscas, JI
AU  - Escude, L
AU  - Miralbell, R
TI  - Hypofractionated stereotactic intensity modulated radiotherapy (IMRT) for prostate cancer with low-metastasic potential
J2  - EJC Suppl
PY  - 2007
VL  - 5
SP  - S477
EP  - S478
ER  - 
TY  - JOUR
LB  - 182.
AU  - Namiki, S
AU  - Ishidoya, S
AU  - Tochigi, T
AU  - Kawamura, S
AU  - Kuwahara, M
AU  - Terai, A
TI  - Health-related quality of life after intensity modulated radiation therapy for localized prostate cancer: Comparison with conventional and conformal radiotherapy
J2  - Jpn J Clin Oncol
PY  - 2006
VL  - 36
SP  - 224
EP  - 230
ER  - 
TY  - JOUR
LB  - 183.
AU  - Perez, CA
AU  - Michalski, JM
AU  - Purdy, JA
AU  - Lockett, MA
TI  - New trends in prostatic cancer research. Three-dimensional conformal radiation therapy (3-D CRT), brachytherapy, and new therapeutic modalities
J2  - Rays
PY  - 2000
VL  - 25
SP  - 331
EP  - 343
ER  - 
TY  - JOUR
LB  - 184.
AU  - Pervez, N
AU  - Pearcey, R
AU  - Parliament, M
AU  - Yee, D
AU  - Amanie, J
AU  - Murtha, A
TI  - Acute toxicity results using dynamic intensity modulated radiotherapy (dIMRT) in high-risk prostate cancer
J2  - Int J Radiat Oncol Biol Phys
PY  - 2007
VL  - 69
SP  - S365
ER  - 
TY  - JOUR
LB  - 185.
AU  - Pollack, A
AU  - Hanlon, A
AU  - Horwitz, EM
AU  - Feigenberg, S
AU  - Uzzo, RG
AU  - Price, RA
TI  - Radiation therapy dose escalation for prostate cancer: a rationale for IMRT
J2  - World J Urol
PY  - 2003
VL  - 21
SP  - 200
EP  - 208
ER  - 
TY  - ELEC
LB  - 186.
AU  - National Cancer Institute
TI  - Comparison of two radiation therapy regimens in treating patients with stage II or III prostate cancer
PY  - 2009
UR  - http://clinicaltrials.gov/ct2/show/NCT00062309
M1  - June 2009
ER  - 
TY  - BOOK
LB  - 187.
AU  - Rembielak, A
TI  - Intensity Modulated Radiation Therapy (IMRT) for prostate cancer patients
CY  - Urol Polska
PY  - 2006
VL  - 59
ER  - 
TY  - JOUR
LB  - 188.
AU  - Reuther, A
AU  - Reddy, C
AU  - Mahadevan, A
AU  - Kupelian, P
TI  - Concomitant irradiation of the entire prostate gland to 70 Gy and the peripheral zone to 80 Gy with intensity modulated radiotherapy in 28 fractions: Preliminary results of a phase II protocol
J2  - Int J Radiat Oncol Biol Phys
PY  - 2006
VL  - 66
SP  - S446
EP  - S447
ER  - 
TY  - JOUR
LB  - 189.
AU  - Ruben, JD
AU  - Davis, S
AU  - Evans, C
AU  - Jones, P
AU  - Gagliardi, F
AU  - Haynes, M
TI  - The effect of intensity-modulated radiotherapy on radiation-induced second malignancies
J2  - Int J Radiat Oncol Biol Phys
PY  - 2008
VL  - 70
SP  - 1530
EP  - 1536
ER  - 
TY  - ELEC
LB  - 190.
AU  - Medical Research Council PR07
TI  - A randomised trial of hormone therapy plus radical radiotherapy versus hormone therapy alone in non-metastatic prostate cancer
PY  - 2009
UR  - http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=651
M1  - June 2009
ER  - 
TY  - JOUR
LB  - 191.
AU  - Sanguineti, G
AU  - Culp, L
AU  - Pena, J
AU  - Bayouth, J
TI  - Acute small bowel and colon toxicity after pelvic IMRT for prostate cancer
J2  - EJC Suppl
PY  - 2003
VL  - 1
SP  - S268
ER  - 
TY  - JOUR
LB  - 192.
AU  - Sanguineti, G
AU  - John, B
AU  - Franzone, P
AU  - Culp, L
AU  - Sosa, M
AU  - Cavey, M
TI  - IMRT to treat the pelvic nodes while escalating the dose to the prostate gland: Acute toxicity data in 45 consecutive patients
J2  - Int J Radiat Oncol Biol Phys
PY  - 2004
VL  - 60
SP  - S466
EP  - S467
ER  - 
TY  - JOUR
LB  - 193.
AU  - Scarbrough, T
AU  - Ting, J
AU  - Feja, L
AU  - Golden, N
AU  - Levitt, C
TI  - Seed marker-based IGRT for prostate cancer: Excellent preliminary toxicity outcomes
J2  - Int J Radiat Oncol Biol Phys
PY  - 2007
VL  - 69
SP  - S322
ER  - 
TY  - JOUR
LB  - 194.
AU  - Singh, A
AU  - Guion, P
AU  - Sears-Crouse, N
AU  - Ullman, K
AU  - Smith, S
AU  - Albert, P
TI  - Whole prostate to 75.6 with concurrent IMRT boost to 95 gray for biopsy proven, MRI defined dominant intraprostatic lesions: Early results of a phase INCI study
J2  - Int J Radiat Oncol Biol Phys
PY  - 2007
VL  - 69
SP  - S369
EP  - S370
ER  - 
TY  - JOUR
LB  - 195.
AU  - Shahar, K
AU  - McGary, J
AU  - Mai, W
AU  - Caillouet, J
AU  - Butler, E
AU  - Teh, B
TI  - Retrospective analysis of late rectal bleeding in prostate cancer patients treated with intensity modulated radiotherapy (IMRT)
J2  - Int J Radiat Oncol Biol Phys
PY  - 2004
VL  - 60
SP  - S459
ER  - 
TY  - JOUR
LB  - 196.
AU  - Soete, G
AU  - Verellen, D
AU  - Storme, G
TI  - Image guided radiotherapy for prostate cancer
J2  - Bull Cancer
PY  - 2008
VL  - 95
SP  - 374
EP  - 380
ER  - 
TY  - JOUR
LB  - 197.
AU  - Su, A
AU  - Gratzle, J
AU  - Correa, D
AU  - Jani, A
TI  - Comparison of chronic GI and GU toxicity of patients with prostate cancer undergoing IMRT vs conventional radiotherapy using localized fields
J2  - Int J Radiat Oncol Biol Phys
PY  - 2006
VL  - 66
SP  - S374
ER  - 
TY  - JOUR
LB  - 198.
AU  - Teh, B
AU  - Mai, W
AU  - Huang, E
AU  - Carpenter, L
AU  - Lu, H
AU  - Chiu, J
TI  - Late gastrointestinal (GI) and genitourinary (GU) toxicity following intensity modulated radiation therapy (IMRT) for prostate cancer
J2  - Int J Radiat Oncol Biol Phys
PY  - 2001
VL  - 51
SP  - 310
EP  - 311
ER  - 
TY  - JOUR
LB  - 199.
AU  - Teh, B
AU  - Bastasch, MD
AU  - Wheeler, TM
AU  - Mai, WY
AU  - Frolov, A
AU  - Uhl, BM
TI  - IMRT for prostate cancer: defining target volume based on correlated pathologic volume of disease
J2  - Int J Radiat Oncol Biol Phys
PY  - 2003
VL  - 56
SP  - 184
EP  - 191
ER  - 
TY  - JOUR
LB  - 200.
AU  - Teh, B
AU  - Mai, W
AU  - McGary, J
AU  - Smiedala, M
AU  - Paulino, A
AU  - Grant, W
TI  - Long-term outcome of a moderate-hypofractionated intensity modulated radiation therapy (IMRT) (77GY at 2.2GY per fraction) approach utilizing immobilization rectal balloon for localized prostate cancer
J2  - Int J Radiat Oncol Biol Phys
PY  - 2007
VL  - 69
SP  - S335
ER  - 
TY  - JOUR
LB  - 201.
AU  - Teslow, T
AU  - Ahmad, S
AU  - Uy, N
AU  - Thomson, W
AU  - Grant, W
AU  - Butler, E
TI  - Comparison of tumor control probability and normal tissue complication probability between 3D-CRT and IMRT plans in patients with prostate cancer
J2  - Eur J Cancer
PY  - 2001
VL  - 37
SP  - S204
EP  - S205
ER  - 
TY  - JOUR
LB  - 202.
AU  - Thakkar, VV
AU  - Khuntia, D
AU  - Reddy, C
AU  - Mahadevan, E
AU  - Klein, A
AU  - Chehade, N
TI  - Hypofractionated intensity modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Long-term outcome results
J2  - Int J Radiat Oncol Biol Phys
PY  - 2005
VL  - 63
SP  - S124
EP  - S125
ER  - 
TY  - JOUR
LB  - 203.
AU  - Yuen, J
AU  - Rodrigues, G
AU  - Trenka, K
AU  - Coad, T
AU  - Yartsev, S
AU  - D’Souza, D
TI  - Comparing two strategies of dynamic intensity modulated radiation therapy (dIMRT) with 3-dimensional conformal radiation therapy (3DCRT) in the hypofractionated treatment of high-risk prostate cancer
J2  - Radiat Oncol
PY  - 2008
VL  - 3
SP  - 1
ER  - 
TY  - JOUR
LB  - 204.
AU  - Vaarkamp, J
TI  - Partial boosting of prostate tumours: Forward planned conformal radiotherapy vs. inverse planned intensity modulated radiotherapy?
J2  - Radiother Oncol
PY  - 2002
VL  - 63
SP  - 232
ER  - 
TY  - ELEC
LB  - 205.
AU  - Villa, SL
AU  - Fantini, N
AU  - Bedini, C
AU  - Sangalli, R
AU  - Valdagni, E
AU  - Pignoli, S
TI  - Acute and bladder rectal toxicities of hypofractionated intensity-modulated radiotherapy (SIB-IMRT) in prostate cancer radical treatment with intraprostatic gold fiducial markers. American Society of Clinical Oncology
PY  - 2008
UR  - www.asco.org/ASCOv2/Meetings/Abstracts?%26vmview=abst_detail_view%26confID=54%26abstractID=20224
M1  - March 2009
ER  - 
TY  - JOUR
LB  - 206.
AU  - Wahab, S
AU  - Michalski, J
AU  - Pierburg, B
AU  - Siegel, C
AU  - Kibel, A
AU  - Low, D
TI  - Pelvic intensity modulated radiation therapy for high risk prostate cancer
J2  - Int J Radiat Oncol Biol Phys
PY  - 2005
VL  - 63
SP  - S331
EP  - S332
ER  - 
TY  - JOUR
LB  - 207.
AU  - Wang, L
AU  - Movsas, B
AU  - Jacob, R
AU  - Fourkal, E
AU  - Chen, L
AU  - Price, R
TI  - Stereotactic IMRT for prostate cancer: dosimetric impact of multileaf collimator leaf width in the treatment of prostate cancer with IMRT
J2  - J Appl Clin Med Phys
PY  - 2004
VL  - 5
SP  - 29
EP  - 41
ER  - 
TY  - JOUR
LB  - 208.
AU  - Wang-Chesebro, A
AU  - Xia, P
AU  - Coleman, J
AU  - Akazawa, C
AU  - Roach, M, III
TI  - Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer
J2  - Int J Radiat Oncol Biol Phys
PY  - 2006
VL  - 66
SP  - 654
EP  - 662
ER  - 
TY  - JOUR
LB  - 209.
AU  - Wong, GW
AU  - Palazzi-Churas, KL
AU  - Jarrard, DF
AU  - Paolone, DR
AU  - Graf, AK
AU  - Hedican, SP
TI  - Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy
J2  - Int J Radiat Oncol Biol Phys
PY  - 2008
VL  - 70
SP  - 449
EP  - 455
ER  - 
TY  - JOUR
LB  - 210.
AU  - Wu, Q
AU  - Arthur, D
AU  - Benedict, S
AU  - Tong, S
AU  - Wu, Y
AU  - Hagan, M
TI  - Intensity-modulated radiotherapy for prostate cancer treatment with nodal coverage
J2  - Int J Radiat Oncol Biol Phys
PY  - 2002
VL  - 54
IS  - Suppl. 2
SP  - 321
ER  - 
TY  - JOUR
LB  - 211.
AU  - Zelefsky, MJ
AU  - Fuks, Z
AU  - Leibel, SA
TI  - Intensity-modulated radiation therapy for prostate cancer
J2  - Semin Radiat Oncol
PY  - 2002
VL  - 12
SP  - 229
EP  - 237
ER  -